Aspirin
Approved · FDAAlso known as 2-Acetoxybenzenecarboxylic acid, 2-Acetoxybenzoic acid, ACETYLSALICYLIC ACID, ASA+134 more
2-Acetoxybenzenecarboxylic acid, 2-Acetoxybenzoic acid, ACETYLSALICYLIC ACID, ASA, Acetylsalicylsäure, Acide acétylsalicylique, Acidum acetylsalicylicum, Acuprin 81, Aggrenox, Alka-Seltzer, Anacin, Anacin Advanced Headache Formula, Anacin Aspirin Regimen, Arthriten Inflammatory Pain, Ascomp, Ascomp with Codeine, Ascriptin, Ascriptin Enteric, Aspergum, Aspi-Cor, Aspidrox, Aspir-Low, Aspir-Mox, Aspircaf, Aspirin-Caffeine, Aspirin-Carisoprodol, Aspirin-Methocarbamol, Aspirin-Oxycodone, Aspirtab, Axotal, Azdone, Azetylsalizylsäure, BC, BC Arthritis, BC Original Formula, Backaid IPF, Bayer Aspirin, Bromo Seltzer Antacid Pain Reliever, Bufferin, Buffex, CP-2, Damason-P, Durlaza, Easprin, Ecotrin, Ecpirin, Emagrin, Empirin, Empirin with Codeine, Endodan, Entaprin, Entercote, Equagesic, Ex-Pain, Exaprin, Exaprin Plus, Excedrin, Excedrin Back and Body, Excedrin Extra Strength Geltab, Excedrin Migraine Geltab, Excedrin PM Triple Action, Fasprin, Fiorinal, Fiorinal with Codeine, Fiormor, Fiortal, Fiortal with Codeine, Fortabs, Genace, Genacote, Genasan, Gennin-FC, Genprin, Halfprin, Idenal, Isollyl, Laniroif, Levacet, Lortab ASA, Magnaprin, Major-Cin, Med Aspirin, Micrainin, Miniprin, Minitabs, Momentum, Norgesic, Norwich Aspirin, O-acetylsalicylic acid, Orphengesic, P-A-C Analgesic, PC-CAP, Pamprin Max Formula, Percodan, Propoxyphene Compound 65, Q-Acin, Rid-A-Pain, Ridiprin, Robaxisal, Roxiprin, Saleto, Sloprin, Soma Compound, Soma Compound with Codeine, St. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Supac, Synalgos-DC, Talwin Compound, Uni-Ann, Uni-Buff, Uni-Case, Uni-Tren, Uricalm Intensive, Valomag, Vanquish, Vazalore, YSP Aspirin, Yosprala, Zero-Order Release, Zorprin, acetyl salicylic acid, acetyl-salicylic acid, acide 2-(acétyloxy)benzoïque, o-acetoxybenzoic acid, ácido acetilsalicílico, Aspir-trin, Aspirina, ASA/Caffeine/Orphenadrine, Acetaminophen/Aspirin/Caffeine, Alor 5/500, Aspirin/Butalbital/Caffeine/Codeine, Aspirin/Oxycodone HCl/Oxycodone Terephthalate, Aspirin/caffeine/dihydrocodeine, Butalbital/Aspirin/Caffeine/Codeine, Panasal 5/500, Salicylic acid acetate, o-carboxyphenyl acetate.
Recent clinical, regulatory, research and industry developments relating to this drug.
The Role of Thomboxane A2 and it's Receptor in Vascular Regulation in Women With Endometriosis
Targeting the Inflammasome With Anti-platelet Therapy: A Mechanistic Study
Supplemental approval: BUTALBITAL, ASPIRIN, CAFEINE, AND CODEINE PHOSPHATE (ANDA075231)
Supplemental approval: BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE (ANDA074951)
Supplemental approval: OXYCODONE AND ASPIRIN (ANDA040910)
Targeted Prevention of Postpartum-Related Breast Cancer
Label change: BUTALBITAL, ASPIRIN, CAFEINE, AND CODEINE PHOSPHATE (ANDA075231)
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- JAMA4
- The New England journal of medicine4
- Cancer medicine1
- Cancers1
- Circulation1
- Circulation. Cardiovascular interventions1
- Angiolillo DJ2
- Avezum A2
- Bass TA2
- Capodanno D2
- Cho DK2
- Connolly SJ2
- Dans AL2
- Diaz R2
- Beth Israel Deaconess Medical Center2
- Myongji Hospital2
- University of Florida College of Medicine-Jacksonville2
- Albert Einstein College of Medicine1
- Brigham and Women's Hospital1
- Chao Family Comprehensive Cancer Center1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 9 of the same disease areas as Aspirin in the shared literature.
Studied across 7 of the same disease areas as Aspirin in the shared literature.
Studied across 6 of the same disease areas as Aspirin in the shared literature.
Studied across 6 of the same disease areas as Aspirin in the shared literature.
Studied across 5 of the same disease areas as Aspirin in the shared literature.
Studied across 4 of the same disease areas as Aspirin in the shared literature.
Studied across 4 of the same disease areas as Aspirin in the shared literature.
Studied across 2 of the same disease areas as Aspirin in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.